Suptavumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | respiratory syncytial virus fusion protein |
| Clinical data | |
| Other names | REGN2222 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H10038N1726O2020S42 |
| Molar mass | 146054.41 g·mol−1 |
Suptavumab (INN;[1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.
This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.[2][3]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
- ^ "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.